Released May 14, 2019, after the close
10-Q filed May 15, 2019, 45 days after period end · 0001564590-19-019236
Q1 2019 · 10-Q
Revenue$8.63M$8.63M +49.0% vs Q1 2018−54.8% vs Q4 2018
Net Income-$14.25M-$14.25M N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.62-$0.62 N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$14,266,000N/M
Operating Cash Flow-$20,145,000N/M
Free Cash Flowderived-$20,421,000N/M
Margins · derived
Operating margin-165.3%+36.7 pt vs Q1 2018
Net margin-165.1%+42.8 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|
| Revenue | $8.63M | $5.79M | $14.85M |
| Net Income | -$14.25M | -$12.05M | -$1.11M |
| EPS Diluted | -$0.62 | -$25.76 | -$2.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR